DOCSLIB.ORG

Supporting Information for Proteomics DOI 10.1002/Pmic.200600056

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supporting Information for Proteomics DOI 10.1002/Pmic.200600056 Supporting Information for Proteomics DOI 10.1002/pmic.200600056 Barbara Celegato, Daniele Capitanio, Mario Pescatori, Chiara Romualdi, Beniamina Pacchioni, Stefano Cagnin, Agnese Vigan, Luca Colantoni, Shajna Begum, Enzo Ricci, Robin Wait, Gerolamo Lanfranchi and Cecilia Gelfi Parallel protein and transcript profiles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal a common impairment of slow to fast fibre differentiation and a general deregulation of MyoD-dependent genes ª 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com Table A. List of genes discriminating among the two classes of patients with the same range of size deletion (EcoRI fragment > 21Kb), but differing by age at biopsy. NA: not available value. Table B. Mass spectrometry data of up and down regulated proteins of unclusterised patients, as shown in Figure 3. Table C. Mass spectrometry data of up and down regulated proteins of patients after gene transcripts cluster analysis. Table D. Common altered genes in FSHD muscle compared to a deltoideous control muscle are listed according to their biological process. Table E. Functionally classified transcripts with an increasing profile according to KpnI repeats number at D4Z4 locus. Single patient ratios and intra-class averaged ratios are reported. Table F. Functionally classified transcripts with a decreasing profile according to KpnI repeats number at D4Z4 locus. Single patient ratios and intra-class averaged ratios are reported. Table G. Ratios values of selected transcripts altered in FSHD muscle, suggesting an enrichment in slow-oxidative fibers in the most severely affected patients. Table H. MyoD target genes with an altered expression in FSHD muscle. Figure A. Hierarchical cluster analysis of the transcriptional expression profiles of 11 FSHD patients. Profiles were obtained using the Human Muscle Array 2.0 platform, which contains 4.801 muscle cDNA probes and are expressed as FSHD deltoid/control. Pearson correlation was used as distance measure. Statistical support for the nodes of the dendrogram is also shown in figure 1A and it is expressed as a fold number percent of a given node over the resampling trials. We chose the bootstrapping genes resampling procedure to build experiment dendrogram and 500 iterations. Patients are clearly divided into 4 groups, according to their EcoRI fragment length. Furthermore, patients with fragment longer than 20kb and age at biopsy >50 years (mean 57.7 +/- 10) are separated from younger (mean 25.7 +/- 5) patients with a comparable fragment size. Below, an enlargement of the global dendrogram showing a selection of the genes discriminating among the classes of patients. Figure B. Percent of differentially expressed genes in each class of FSHD patients, grouped by their biological function. Note that some functional categories are specifically affected in one class of patients. Figure C. Correlation between protein and transcript expression levels of myosin heavy chains (MYH1, MYH7, MYH2) averaged among patients of the same class. Table A Human Muscle Array 2.0 Expression ratios (FSHD/control) Averaged expression ratios Gene name and biological process Chr pos Archive ID Group A Group > 50 years Group A Group > 50 years 4 - 23 Kb 3 - 26 Kb 6 - 21 Kb 1 - 27 Kb 5 - 23 Kb 2 - 27 Kb Frgm > 21Kb Oxidative phosphorilation 2-001A09 cytochrome c oxidase subunit VIa, pol 2 (COX6A2) 16 -1.18 -1.18 1.09 1.2 1.18 1.14 -1.08 1.18 2-001G05 cytochrome c oxidase subunit VIIb (COX7B) X -1.04 -1.2 -1.01 1.24 1.1 1.11 -1.08 1.15 2-003E10 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 (NDUFC1) 4 -1.11 -1.19 1.06 1.03 -1.05 1.25 -1.07 1.08 Protein biosynthesis 2-001D07 ribosomal protein S18 (RPS18) 6 -1.12 -1.23 1.14 -1 1.02 1.22 -1.05 1.08 2-001G01 ribosomal protein S8 (RPS8) 1 -1.08 -1.14 1.15 1.15 1.11 1.11 -1.02 1.12 2-018H06 mitochondrial ribosomal protein L46 (MRPL46) 15 -1.22 -1.22 -1.11 1.06 1.06 1.1 -1.18 1.07 2-018H02 aspartyl aminopeptidase (DNPEP) 2 -1.14 -1.14 -1.07 1.01 1.18 1.14 -1.12 1.11 Proteolysis 2-017D05 ubiquitin protein ligase E3A (UBE3A) 15 -1.33 -1.33 1.05 1.09 1.15 1.08 -1.18 1.1 2-029A02 cathepsin B (CTSB) 8 2.01 2.25 2.1 -2 -1.76 -1.94 2.12 -1.89 2-033C05 KIAA0317 gene product 14 2.35 1.89 2.11 -1.9 -1.42 -1.64 2.12 -1.63 Muscle contraction 2-008A02 creatine kinase, muscle (CKM) 19 -1.25 -1.16 -1.06 1.04 1.18 1.11 -1.15 1.11 2-021E11 tropomyosin 2 (beta) 9 2.35 2.19 1.9 -1.72 -1.4 -1.39 2.15 -1.49 2-021C11 tropomyosin 2 (beta) 9 2.29 1.95 1.82 -1.48 -1.56 -1.45 2.02 -1.49 2-001A05 titin-cap (telethonin) (TCAP) 17 2.28 1.88 1.84 -1.93 -1.33 -1.79 2 -1.64 2-010H06 troponin C2, fast (TNNC2) 20 -1.24 -1.2 -1.05 1.01 1.2 1.16 -1.16 1.12 2-022B02 troponin I, skeletal, fast (TNNI2) 11 2.7 1.95 1.64 -2.21 -1.22 -1.46 2.09 -1.53 2-024D08 troponin T1, skeletal, slow (TNNT1) 19 3.55 2.51 2.3 -2.23 -1.38 -2.18 2.79 -1.84 2-024F02 troponin T1, skeletal, slow (TNNT1) 19 3.04 2.99 1.82 -2.22 -1.37 -2.03 2.62 -1.79 2-023F09 troponin T1, skeletal, slow (TNNT1) 19 3.2 3.07 2.31 -2.09 -1.19 -2.02 2.86 -1.66 2-021E03 troponin T1, skeletal, slow (TNNT1) 19 3.35 2.35 1.88 -1.91 -1.44 -2.16 2.53 -1.79 2-023H12 troponin T1, skeletal, slow (TNNT1) 19 3.11 3.12 1.67 -1.85 -1.13 -1.68 2.64 -1.49 2-001A12 troponin T1, skeletal, slow (TNNT1) 19 2.43 2.17 1.72 -1.2 -1.35 -1.6 2.11 -1.37 2-020A10 troponin T3, skeletal, fast (TNNT3) 11 4.86 5.51 4.03 -2.56 -2.16 -1.62 4.8 -2.04 2-001H06 troponin T3, skeletal, fast (TNNT3) 11 4.6 5.46 3.84 -2.11 -1.49 -1.37 4.63 -1.6 Cell cycle control 2-008G02 zinc finger, HIT domain containing 1 7 -1.09 -1.12 -1.09 1.06 1.15 1.12 -1.1 1.11 2-007F05 protein phosphatase 2A, regulatory subunit B (PR 53) 9 -1.13 -1.2 1 1.11 1.13 1.18 -1.1 1.14 BL-007F08 retinoblastoma binding protein 7 (RBBP7) X -1.11 -1.16 1.01 1.11 1.21 1.23 -1.08 1.19 Apoptosis BL-001B06 BH3 interacting domain death agonist (BID) 22 -1.14 -1.17 1.03 1.03 NA 1.17 -1.09 1.1 2-029A02 cathepsin B (CTSB) 8 2.01 2.25 2.1 -2 -1.76 -1.94 2.12 -1.8 Regulation of transcription 2-011H11 transcription factor LZIP mRNA (CREB3) 9 -1.13 -1.15 -1.1 1.03 1.22 1.19 -1.12 1.15 2-029C02 myocyte enhancer factor 2C (MEF2C) 5 -1.35 -1.36 -1.45 1.06 1.03 1.18 -1.39 1.09 Extracellular matrix 2-025E09 laminin, alpha 4 (LAMA4) 6 4.76 4.51 3.36 -1.77 -1.76 -1.5 4.21 -1.67 2-016C10 laminin, beta 2 (laminin S) (LAMB2) 3 -1.22 -1.22 -1.01 1.14 1.12 1.16 -1.14 1.14 Other 2-009A04 lamin B1 (LMNB1) 5 -1.3 -1.15 1.08 1.06 1.03 1.12 -1.1 1.07 2-015F09 voltage-dependent anion channel 2 (VDAC2) 10 -1.13 -1.23 1.04 1.19 1.26 1.18 -1.09 1.21 2-018H10 PDZ and LIM domain 2 (mystique) 8 -1.18 -1.31 -1.12 1.15 1.21 1.17 -1.2 1.18 2-003B09 monoglyceride lipase 3 -1.16 -1.26 -1.01 1.08 1.28 1.2 -1.14 1.19 2-016G12 B-cell associated protein (REA) 12 -1.01 -1.27 -1.01 1.21 1.08 1.18 -1.08 1.16 2-016B11 coatomer protein complex, subunit epsilon (COPE) 19 -1.27 -1.22 -1.01 1.2 1.24 1.22 -1.15 1.22 BL-002H11 arachidonate 5-lipoxygenase-activating protein (ALOX5AP) 13 -1.14 -1.2 -1.08 1.12 1.04 1.18 -1.14 1.11 BL-002F03 sorting nexin 17 2 -1.17 -1.15 -1.04 -1.01 1.17 1.1 -1.12 1.09 BL-003H07 formin-like (FMNL) 17 -1.09 -1.17 -1.12 1.06 1.16 1.16 -1.12 1.12 2-029G06 SNARE associated protein snapin 1 -1.19 -1.11 -1.07 -1.04 1.1 1.11 -1.12 1.06 2-012D10 SEC13-like 1 3 -1.21 -1.41 -1.02 1.1 1.18 1.22 -1.19 1.16 Unknown 2-017E07 haloacid dehalogenase-like hydrolase domain containing 1A (GS1) X -1.09 -1.16 1.1 1.16 1.18 1.03 -1.04 1.12 2-005A01 aurora-A kinase interacting protein (AKIP) 1 -1.06 -1.24 1.1 1.22 1.1 1.12 -1.05 1.15 BL-002B09 hypothetical protein LOC51234 15 -1.1 -1.27 1.06 -1.03 -1 1.21 -1.09 1.06 2-008F10 unknown seqeunce from clone RP11-545E24 1 -1.21 -1.38 -1.02 1.15 1.18 1.2 -1.18 1.18 2-017C01 unknown seqeunce from clone CTD-2545M3 19 -1.33 -1.49 -1.04 1.02 1.06 1.19 -1.26 1.09 2-013D10 hypothetical protein FLJ10769 (FLJ10769) 13 -1.19 -1.37 -1.01 1.08 1.12 1.12 -1.17 1.11 2-001H10 ankyrin repeat domain 23 2 -1.31 -1.29 -1.12 -1.01 -1 -1.02 -1.23 -1.01 2-033G02 unknown sequence from PAC clone RP4-745K6 17 -1.15 -1.24 1.17 1.19 1.25 1.08 -1.05 1.17 2-017B04 chromosome 5 open reading frame 13 5 -1.24 -1.3 1.08 1.02 1.08 1.04 -1.13 1.05 2-020D03 SCIRP10-related protein 1 5.2 6.19 4.14 -1.73 -1.84 -1.57 5.17 -1.71 BL-002B05 zinc finger, ZZ domain containing 3 (ZZZ3) 1 -1.11 -1.2 -1.11 1.04 1.14 1.15 -1.14 1.11 2-012H02 chromosome 20 open reading frame 111 20 -1.13 -1.28 -1.02 1.11 1.14 1.18 -1.13 1.14 2-011G09 chromosome 2 open reading frame 24 2 NA -1.4 1.12 1.11 1.11 1.19 -1.09 1.14 2-005C06 hypothetical gene supported by BC055092 8 2.34 2.85 1.8 -1.55 -1.44 NA 2.33 -1.49 2-005F01 selenoprotein O 22 -1.05 -1.19 -1.05 1.15 1.14 1.15 -1.09 1.15 Table B FSHD Upregulated proteins: Swissprot/ MW (Da) MW (Da) TrEMBL pI using pI using calculated Spot Spot AC ExPASy calculated ExPASy from 2D- volume volume log2 spot N° Number Protein p-value tool from 2D-gel tool gel Control FSHD (FSHD/Control) Contraction/structur al proteins: 201 P02675 Fibrinogen beta chain precursor 0.006 8.54 8.50 55 928.15 52 673 0.043 0.073 0.76 99 O75083 WD repeat prot, 1 0.018 6.17 6.99 66 193.52 69 178 0.003 0.004 0.42 Anaerobic metabolism: 191 P00352 Aldehyde DH 1A1 0.006 6.29 6.94 54 730.65 53 304 0.039 0.097 1.31 248 P06733 Alpha enolase 0.008 6.99 7.07 47 037.77 46 415 0.159 0.219 0.46 331 P17174 Aspartate aminotransferase, cytoplasmic 0.004 6.57 7.64 46 116.31 39 931 0.059 0.111 0.91 323 P17174 Aspartate aminotransferase, cytoplasmic 0.004 6.57 7.70 46 116.31 40 573 0.09 0.15 0.74 271 P13929 Beta enolase
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • Role of Active Contraction and Tropomodulins in Regulating Actin Filament Length and Sarcomere Structure in Developing Zebrafish Skeletal Muscle
    ORIGINAL RESEARCH published: 31 March 2016 doi: 10.3389/fphys.2016.00091 Role of Active Contraction and Tropomodulins in Regulating Actin Filament Length and Sarcomere Structure in Developing Zebrafish Skeletal Muscle Lise Mazelet 1, Matthew O. Parker 2, Mei Li 3, Anders Arner 3 and Rachel Ashworth 4* 1 School of Biological and Chemical Sciences, Queen Mary, University of London, London, UK, 2 School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK, 3 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 4 The Blizard Institute/Institute of Health Sciences Education, Barts and The London School of Medicine and Dentistry, London, UK Whilst it is recognized that contraction plays an important part in maintaining the structure and function of mature skeletal muscle, its role during development remains undefined. In this study the role of movement in skeletal muscle maturation was investigated in intact zebrafish embryos using a combination of genetic and pharmacological approaches. An immotile mutant line (cacnb1ts25) which lacks functional voltage-gated calcium channels (dihydropyridine receptors) in the muscle and pharmacological immobilization of embryos Edited by: with a reversible anesthetic (Tricaine), allowed the study of paralysis (in mutants and Catherine Coirault, anesthetized fish) and recovery of movement (reversal of anesthetic treatment). The Institut National de la Santé et de la Recherche Médicale, France effect of paralysis in early embryos (aged between 17 and 24 hours post-fertilization, hpf) Reviewed by: on skeletal muscle structure at both myofibrillar and myofilament level was determined Corrado Poggesi, using both immunostaining with confocal microscopy and small angle X-ray diffraction.
    [Show full text]
  • Lineage-Specific Programming Target Genes Defines Potential for Th1 Temporal Induction Pattern of STAT4
    Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021 is online at: average * The Journal of Immunology published online 26 August 2009 from submission to initial decision 4 weeks from acceptance to publication J Immunol http://www.jimmunol.org/content/early/2009/08/26/jimmuno l.0901411 Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming Seth R. Good, Vivian T. Thieu, Anubhav N. Mathur, Qing Yu, Gretta L. Stritesky, Norman Yeh, John T. O'Malley, Narayanan B. Perumal and Mark H. Kaplan Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2009/08/26/jimmunol.090141 1.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 1, 2021. Published August 26, 2009, doi:10.4049/jimmunol.0901411 The Journal of Immunology Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming1 Seth R. Good,2* Vivian T. Thieu,2† Anubhav N. Mathur,† Qing Yu,† Gretta L.
    [Show full text]
  • Table SII. Significantly Differentially Expressed Mrnas of GSE23558 Data Series with the Criteria of Adjusted P<0.05 And
    Table SII. Significantly differentially expressed mRNAs of GSE23558 data series with the criteria of adjusted P<0.05 and logFC>1.5. Probe ID Adjusted P-value logFC Gene symbol Gene title A_23_P157793 1.52x10-5 6.91 CA9 carbonic anhydrase 9 A_23_P161698 1.14x10-4 5.86 MMP3 matrix metallopeptidase 3 A_23_P25150 1.49x10-9 5.67 HOXC9 homeobox C9 A_23_P13094 3.26x10-4 5.56 MMP10 matrix metallopeptidase 10 A_23_P48570 2.36x10-5 5.48 DHRS2 dehydrogenase A_23_P125278 3.03x10-3 5.40 CXCL11 C-X-C motif chemokine ligand 11 A_23_P321501 1.63x10-5 5.38 DHRS2 dehydrogenase A_23_P431388 2.27x10-6 5.33 SPOCD1 SPOC domain containing 1 A_24_P20607 5.13x10-4 5.32 CXCL11 C-X-C motif chemokine ligand 11 A_24_P11061 3.70x10-3 5.30 CSAG1 chondrosarcoma associated gene 1 A_23_P87700 1.03x10-4 5.25 MFAP5 microfibrillar associated protein 5 A_23_P150979 1.81x10-2 5.25 MUCL1 mucin like 1 A_23_P1691 2.71x10-8 5.12 MMP1 matrix metallopeptidase 1 A_23_P350005 2.53x10-4 5.12 TRIML2 tripartite motif family like 2 A_24_P303091 1.23x10-3 4.99 CXCL10 C-X-C motif chemokine ligand 10 A_24_P923612 1.60x10-5 4.95 PTHLH parathyroid hormone like hormone A_23_P7313 6.03x10-5 4.94 SPP1 secreted phosphoprotein 1 A_23_P122924 2.45x10-8 4.93 INHBA inhibin A subunit A_32_P155460 6.56x10-3 4.91 PICSAR P38 inhibited cutaneous squamous cell carcinoma associated lincRNA A_24_P686965 8.75x10-7 4.82 SH2D5 SH2 domain containing 5 A_23_P105475 7.74x10-3 4.70 SLCO1B3 solute carrier organic anion transporter family member 1B3 A_24_P85099 4.82x10-5 4.67 HMGA2 high mobility group AT-hook 2 A_24_P101651
    [Show full text]
  • 1471-2164-2-7.Pdf
    BMC Genomics BioMed Central BMC Genomics :7 Research2 2001, article Genomic organization of Tropomodulins 2 and 4 and unusual intergenic and intraexonic splicing of YL-1 and Tropomodulin 4 Patrick R Cox1, Teepu Siddique5 and Huda Y Zoghbi*1,2,3,4 Address: 1Division of Neuroscience, Baylor College of Medicine, Houston, Texas, USA, 2Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA, 3Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA, 4Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas, USA and 5Baylor College of Medicine, Houston, Northwestern University Medical School, Chicago, Illinois, USA E-mail: Patrick R Cox - [email protected]; Teepu Siddique - [email protected]; Huda Y Zoghbi* - [email protected] *Corresponding author Published: 17 October 2001 Received: 13 July 2001 Accepted: 17 October 2001 BMC Genomics 2001, 2:7 This article is available from: http://www.biomedcentral.com/1471-2164/2/7 © 2001 Cox et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [email protected] Abstract Background: The tropomodulins (TMODs) are a family of proteins that cap the pointed ends of actin filaments. Four TMODs have been identified in humans, with orthologs in mice. Mutations in actin or actin-binding proteins have been found to cause several human diseases, ranging from hypertrophic cardiomyopathy to immunodefiencies such as Wiskott-Aldrich syndrome. We had previously mapped Tropomodulin 2 (TMOD2) to the genomic region containing the gene for amyotrophic lateral sclerosis 5 (ALS5).
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Transcriptomic Analysis of Cortical Versus Cancellous Bone in Response to Mechanical Loading and Estrogen Signaling
    TRANSCRIPTOMIC ANALYSIS OF CORTICAL VERSUS CANCELLOUS BONE IN RESPONSE TO MECHANICAL LOADING AND ESTROGEN SIGNALING A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Natalie H Kelly January 2017 © 2017 Natalie H Kelly TRANSCRIPTOMIC ANALYSIS OF CORTICAL VERSUS CANCELLOUS BONE IN RESPONSE TO MECHANICAL LOADING AND ESTROGEN SIGNALING Natalie H Kelly, Ph. D. Cornell University 2017 Osteoporosis is a skeletal disease characterized by low bone mass that often results in fracture. Mechanical loading of the skeleton is a promising approach to maintain or recover bone mass. Mouse models of in vivo loading differentially increase bone mass in cortical and cancellous sites. The molecular mechanisms behind this anabolic response to mechanical loading need to be determined and compared between cortical and cancellous bone. This knowledge could enhance the development of drug therapies to increase bone formation in osteoporotic patients. After developing a method to isolate high-quality RNA from marrow- free mouse cortical and cancellous bone, differences in gene transcription were determined at baseline and at two time points following mechanical loading of wild-type mice. Cortical and cancellous bone exhibited different transcriptional profiles at baseline and in response to mechanical loading. Enhanced Wnt signaling dominated the response in cortical bone at both time points, but in cancellous bone only at the early time point. In cancellous bone at the later time point, many muscle-related genes were downregulated. Decreased bioavailable estrogen levels are a major cause of bone loss in postmenopausal women.
    [Show full text]
  • Tropomodulin 4 (TMOD4) (NM 013353) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP304673 Tropomodulin 4 (TMOD4) (NM_013353) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human tropomodulin 4 (muscle) (TMOD4) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 39.2 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_037485 Locus ID: 29765 UniProt ID: Q9NZQ9 RefSeq Size: 1322 Cytogenetics: 1q21.3 RefSeq ORF: 1035 Synonyms: SK-TMOD Summary: Blocks the elongation and depolymerization of the actin filaments at the pointed end. The Tmod/TM complex contributes to the formation of the short actin protofilament, which in turn defines the geometry of the membrane skeleton.[UniProtKB/Swiss-Prot Function] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Tropomodulin 4 (TMOD4) (NM_013353) Human Recombinant Protein – TP304673 Product images: Coomassie blue staining of purified TMOD4 protein (Cat# TP304673).
    [Show full text]
  • Distribution Agreement
    Distribution Agreement In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. Signature: _____________________________ ______________ Ivan Ludlow Date MDMA’s Effect on Myocardial DNA Methylation and its Association with Dilated Cardiomyopathy By Ivan Ludlow Master of Public Health Environmental Health _________________________________________ William Michael Caudle, Ph.D. Committee Chair _________________________________________ Paige Tolbert, Ph.D. Committee Member _________________________________________ William Lewis, M.D. Committee Member MDMA’s Effect on Myocardial DNA Methylation and its Association with Dilated Cardiomyopathy By Ivan Ludlow B.S. Emory University 2014 Thesis Committee Chair: William Michael Caudle, Ph.D. An abstract of A thesis submitted to the Faculty of the Rollins School of Public Health of Emory University in partial fulfillment of the requirements for the degree of Master of Public Health in Environmental Health 2015 Abstract MDMA’s Effect on Myocardial DNA Methylation and its Association with Dilated Cardiomyopathy By Ivan Ludlow MDMA (“Ecstasy”) is an illicit psychoactive drug that has increased in popularity in the past two decades.
    [Show full text]
  • Title Epithelial TRAF6 Drives IL-17-Mediated Psoriatic
    Epithelial TRAF6 drives IL-17-mediated psoriatic Title inflammation( Dissertation_全文 ) Author(s) Matsumoto, Reiko Citation 京都大学 Issue Date 2019-03-25 URL https://doi.org/10.14989/doctor.k21634 Right Type Thesis or Dissertation Textversion ETD Kyoto University RESEARCH ARTICLE Epithelial TRAF6 drives IL-17–mediated psoriatic inflammation Reiko Matsumoto,1 Teruki Dainichi,1 Soken Tsuchiya,2 Takashi Nomura,1 Akihiko Kitoh,1 Matthew S. Hayden,3 Ken J. Ishii,4,5 Mayuri Tanaka,4,5 Tetsuya Honda,1 Gyohei Egawa,1 Atsushi Otsuka,1 Saeko Nakajima,1 Kenji Sakurai,1 Yuri Nakano,1 Takashi Kobayashi,6 Yukihiko Sugimoto,2 and Kenji Kabashima1,7 1Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2Department of Pharmaceutical Biochemistry, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan. 3Section of Dermatology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. 4Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan. 5Laboratory of Vaccine Science, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. 6Department of Infectious Disease Control, Faculty of Medicine, Oita University, Oita, Japan. 7Singapore Immunology Network (SIgN) and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore. Epithelial cells are the first line of defense against external dangers, and contribute to induction of adaptive immunity including Th17 responses. However, it is unclear whether specific epithelial signaling pathways are essential for the development of robust IL-17–mediated immune responses. In mice, the development of psoriatic inflammation induced by imiquimod required keratinocyte TRAF6. Conditional deletion of TRAF6 in keratinocytes abrogated dendritic cell activation, IL-23 production, and IL-17 production by γδ T cells at the imiquimod-treated sites.
    [Show full text]
  • Effects of 12 Weeks of Hypertrophy Resistance Exercise Training
    nutrients Article Effects of 12 Weeks of Hypertrophy Resistance Exercise Training Combined with Collagen Peptide Supplementation on the Skeletal Muscle Proteome in Recreationally Active Men Vanessa Oertzen-Hagemann 1,*, Marius Kirmse 1, Britta Eggers 2 , Kathy Pfeiffer 2, Katrin Marcus 2, Markus de Marées 1 and Petra Platen 1 1 Department of Sports Medicine and Sports Nutrition, Ruhr University Bochum, 44801 Bochum, Germany; [email protected] (M.K.); [email protected] (M.d.M.); [email protected] (P.P.) 2 Medizinisches Proteom-Center, Medical Faculty, Ruhr University Bochum, 44801 Bochum, Germany; [email protected] (B.E.); kathy.pfeiff[email protected] (K.P.); [email protected] (K.M.) * Correspondence: [email protected]; Tel.: +49-234-32-23170 Received: 10 April 2019; Accepted: 10 May 2019; Published: 14 May 2019 Abstract: Evidence has shown that protein supplementation following resistance exercise training (RET) helps to further enhance muscle mass and strength. Studies have demonstrated that collagen peptides containing mostly non-essential amino acids increase fat-free mass (FFM) and strength in sarcopenic men. The aim of this study was to investigate whether collagen peptide supplementation in combination with RET influences the protein composition of skeletal muscle. Twenty-five young men (age: 24.2 2.6 years, body mass (BM): 79.6 5.6 kg, height: 185.0 5.0 cm, fat mass (FM): ± ± ± 11.5% 3.4%) completed body composition and strength measurements and vastus lateralis biopsies ± were taken before and after a 12-week training intervention. In a double-blind, randomized design, subjects consumed either 15 g of specific collagen peptides (COL) or a non-caloric placebo (PLA) every day within 60 min after their training session.
    [Show full text]
  • Aberrant Developmental Titin Splicing and Dysregulated
    Aberrant developmental titin splicing and dysregulated sarcomere length in Thymosin 4 knockout mice Smart, Nicola; Riegler, Johannes; Turtle, Cameron W.; Lygate, Craig A.; McAndrew, Debra J; Gehmlich, Katja; Dubé, Karina N.; Price, Anthony N.; Muthurangu, Vivek; Taylor, Andrew M.; Lythgoe, Mark F; Redwood, Charles; Riley, Paul R. DOI: 10.1016/j.yjmcc.2016.10.010 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Smart, N, Riegler, J, Turtle, CW, Lygate, CA, McAndrew, DJ, Gehmlich, K, Dubé, KN, Price, AN, Muthurangu, V, Taylor, AM, Lythgoe, MF, Redwood, C & Riley, PR 2017, 'Aberrant developmental titin splicing and dysregulated sarcomere length in Thymosin 4 knockout mice', Journal of Molecular and Cellular Cardiology, vol. 102, pp. 94- 107. https://doi.org/10.1016/j.yjmcc.2016.10.010 Link to publication on Research at Birmingham portal General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.
    [Show full text]